Literature DB >> 22120269

Cost-effectiveness of minimally invasive versus open transforaminal lumbar interbody fusion for degenerative spondylolisthesis associated low-back and leg pain over two years.

Scott L Parker1, Owoicho Adogwa, Ali Bydon, Joseph Cheng, Matthew J McGirt.   

Abstract

OBJECTIVE: Minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) for lumbar spondylolisthesis allows for surgical treatment of back and leg pain while theoretically minimizing tissue injury and accelerating overall recovery. Although the authors of previous studies have demonstrated shorter length of hospital stay and reduced blood loss with MIS versus open-TLIF, short- and long-term outcomes have been similar. No studies to date have evaluated the comprehensive health care costs associated with TLIF procedures or assessed the cost-utility of MIS- versus open-TLIF. As such, we set out to assess previously unstudied end points of health care cost and cost-utility associated with MIS- versus open-TLIF.
METHODS: Thirty patients undergoing MIS-TLIF (n=15) or open-TLIF (n=15) for grade I degenerative spondylolisthesis associated back and leg pain were prospectively studied. Total back-related medical resource use, missed work, and health-state values (quality-adjusted life years [QALYs], calculated from EQ-5D with U.S. valuation) were assessed after two-year follow-up. Two-year resource use was multiplied by unit costs on the basis of Medicare national allowable payment amounts (direct cost) and work-day losses were multiplied by the self-reported gross-of-tax wage rate (indirect cost). Difference in mean total cost per QALY gained for MIS- versus open-TLIF was assessed as incremental cost-effectiveness ratio (ICER: COSTmis-COSTopen/QALYmis-QALYopen).
RESULTS: MIS versus open-TLIF cohorts were similar at baseline. By two years postoperatively, patients undergoing MIS- versus open-TLIF reported similar mean QALYs gained (0.50 vs. 0.41, P=0.17). Mean total two-year cost of MIS- and open-TLIF was $35,996 and $44,727, respectively. The $8,731 two-year cost savings of MIS- versus open-TLIF did not reach statistical significance (P=0.18) for this sample size.
CONCLUSIONS: Although our limited sample size prevented statistical significance, MIS- versus open-TLIF was associated with reduced costs over two years while providing equivalent improvement in QALYs. MIS-TLIF allows patients to leave the hospital sooner, achieve narcotic independence sooner, and return to work sooner than open-TLIF. In our experience, MIS- versus open-TLIF is a cost reducing technology in the surgical treatment of medically refractory low-back and leg pain from grade I lumbar spondylolisthesis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22120269     DOI: 10.1016/j.wneu.2011.09.013

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  34 in total

1.  Surgery for degenerative spondylolisthesis: open versus minimally invasive surgery.

Authors:  Charles A Reitman; D Greg Anderson; Jeff Fischgrund
Journal:  Clin Orthop Relat Res       Date:  2013-07-20       Impact factor: 4.176

2.  Expert's comment concerning Grand Rounds case entitled "Minimal access bilateral transforaminal lumbar interbody fusion for high-grade isthmic spondylolisthesis" (by Nasir A. Quraishi and Y. Raja Rampersaud; doi:10.1007/s00586-012-2623-2).

Authors:  Christof Birkenmaier
Journal:  Eur Spine J       Date:  2013-07-19       Impact factor: 3.134

Review 3.  MIS lateral spine surgery: a systematic literature review of complications, outcomes, and economics.

Authors:  Jeff A Lehmen; Edward J Gerber
Journal:  Eur Spine J       Date:  2015-04-08       Impact factor: 3.134

Review 4.  Cost-utility of minimally invasive versus open transforaminal lumbar interbody fusion: systematic review and economic evaluation.

Authors:  Kevin Phan; Jarred A Hogan; Ralph J Mobbs
Journal:  Eur Spine J       Date:  2015-07-21       Impact factor: 3.134

5.  South Korean degenerative spondylolisthesis patients had surgical treatment at earlier age than Japanese, American, and European patients: a published literature observation.

Authors:  Zoltán Káplár; Yì-Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2016-12

Review 6.  Degenerative spondylolisthesis: contemporary review of the role of interbody fusion.

Authors:  Joseph F Baker; Thomas J Errico; Yong Kim; Afshin Razi
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-11-25

7.  Impact of old age on patient-report outcomes and cost utility for anterior cervical discectomy and fusion surgery for degenerative spine disease.

Authors:  Silky Chotai; Scott L Parker; J Alex Sielatycki; Ahilan Sivaganesan; Harrison F Kay; Joseph B Wick; Matthew J McGirt; Clinton J Devin
Journal:  Eur Spine J       Date:  2016-11-24       Impact factor: 3.134

8.  Improvements in Back and Leg Pain Following a Minimally Invasive Transforaminal Lumbar Interbody Fusion.

Authors:  Dustin H Massel; Benjamin C Mayo; Ankur S Narain; Fady Y Hijji; Philip K Louie; Nathaniel W Jenkins; James M Parrish; Kern Singh
Journal:  Int J Spine Surg       Date:  2020-10

9.  A retrospective review comparing two-year patient-reported outcomes, costs, and healthcare resource utilization for TLIF vs. PLF for single-level degenerative spondylolisthesis.

Authors:  Elliott Kim; Silky Chotai; David Stonko; Joseph Wick; Alex Sielatycki; Clinton J Devin
Journal:  Eur Spine J       Date:  2017-06-05       Impact factor: 3.134

10.  Minimally invasive versus open transforaminal lumbar interbody fusion: a meta-analysis based on the current evidence.

Authors:  Nai-Feng Tian; Yao-Sen Wu; Xiao-Lei Zhang; Hua-Zi Xu; Yong-Long Chi; Fang-Min Mao
Journal:  Eur Spine J       Date:  2013-04-10       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.